ABOS Quote, Financials, Valuation and Earnings

Kodiak Sciences has a net margin of -- compared to Acumen Pharmaceuticals's net margin of --. Acumen Pharmaceuticals's return on equity of -- beat Kodiak Sciences's return on equity of --.

Acumen Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 468.42%. On the other hand Kodiak Sciences has an analysts' consensus of $6.67 which suggests that it could fall by -26.9%. Given that Acumen Pharmaceuticals has higher upside potential than Kodiak Sciences, analysts believe Acumen Pharmaceuticals is more attractive than Kodiak Sciences.

Acumen Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Kodiak Sciences has a beta of 2.113, suggesting its more volatile than the S&P 500 by 111.317%.

Acumen Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kodiak Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Acumen Pharmaceuticals pays -- of its earnings as a dividend. Kodiak Sciences pays out -- of its earnings as a dividend.

Acumen Pharmaceuticals quarterly revenues are --, which are smaller than Kodiak Sciences quarterly revenues of --. Acumen Pharmaceuticals's net income of -$29.8M is higher than Kodiak Sciences's net income of -$43.9M. Notably, Acumen Pharmaceuticals's price-to-earnings ratio is -- while Kodiak Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acumen Pharmaceuticals is -- versus -- for Kodiak Sciences. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Acumen Pharmaceuticals's net margin of -49.65%. Acumen Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Acumen Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 468.42%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 503.14%. Given that NovaBay Pharmaceuticals has higher upside potential than Acumen Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than Acumen Pharmaceuticals.

Acumen Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Acumen Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Acumen Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Acumen Pharmaceuticals quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Acumen Pharmaceuticals's net income of -$29.8M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Acumen Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acumen Pharmaceuticals is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Acumen Pharmaceuticals's net margin of -2357.27%. Acumen Pharmaceuticals's return on equity of -- beat Palatin Technologies's return on equity of --.

Acumen Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 468.42%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1140.88%. Given that Palatin Technologies has higher upside potential than Acumen Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Acumen Pharmaceuticals.

Acumen Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.

Acumen Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Acumen Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Acumen Pharmaceuticals quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Acumen Pharmaceuticals's net income of -$29.8M is lower than Palatin Technologies's net income of -$7.8M. Notably, Acumen Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acumen Pharmaceuticals is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Acumen Pharmaceuticals's net margin of --. Acumen Pharmaceuticals's return on equity of -- beat Theriva Biologics's return on equity of --.

Acumen Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 468.42%. On the other hand Theriva Biologics has an analysts' consensus of -- which suggests that it could grow by 5591.82%. Given that Theriva Biologics has higher upside potential than Acumen Pharmaceuticals, analysts believe Theriva Biologics is more attractive than Acumen Pharmaceuticals.

Acumen Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.367%.

Acumen Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Acumen Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Acumen Pharmaceuticals quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Acumen Pharmaceuticals's net income of -$29.8M is lower than Theriva Biologics's net income of -$7.7M. Notably, Acumen Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acumen Pharmaceuticals is -- versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.